Maxim Biomedical, Inc.

Maxim Biomedical, Inc., a self-certified small disadvantaged business and Asian-Pacific American-owned manufacturer of in-vitro diagnostic substances based in Rockville, Maryland, supplies federal agencies with COVID-19 diagnostic tests and related medical devices as a prime contractor operating on full-and-open and non-set-aside basis. The company is a for-profit manufacturer with no participation in 8(a), HUBZone, SDVOSB, or other SBA set-aside vehicles; recent awards span multiple fiscal years with operations at facilities in Chambersburg, Pennsylvania, Frederick, Maryland, and other locations.

Maxim's federal customer base concentrates heavily on defense and public-health procurement, with 85% of awards spanning five distinct agencies. The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense dominates by dollar value, accounting for 4 awards worth $100.5 million in combined potential value, anchored by a $54.64 million definitive contract (February 2022 through July 2022) for 8 million over-the-counter COVID-19 antigen test kits manufactured in Chambersburg. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response placed 2 awards totaling $52.2 million in combined potential value, including a $49.536 million firm-fixed-price definitive contract (awarded September 20, 2023, completing March 19, 2025) for over-the-counter COVID-19 tests and a $2.7 million contract completed in February 2023. HHS Centers for Disease Control and Prevention entities hold 16 awards across two offices with combined potential value of $387 thousand. The National Heart Lung and Blood Institute contributed 1 award worth $5.3 million. The Navy Bureau of Medicine and Surgery placed a $155 thousand purchase order (awarded May 19, 2026, completing May 18, 2027) for a multiplex blind-spot LFI supply kit. Overall combined potential value across 27 prime awards reaches $158.6 million, with $113 million obligated (71% of potential).

Maxim operates exclusively as a prime contractor — all 27 awards in the portfolio are prime contracts with zero subcontract activity. A single Indefinite Delivery Contract (W911QY20D0018) appears in the parent-vehicle data, carrying 1 task order and $171 thousand in combined potential value. Award pace has been episodic: 5 awards in 2020, 3 in 2019, 2 in 2022, 1 in 2023, and 1 in 2026, reflecting project-driven procurement cycles rather than sustained recurring work. One award — the May 2026 Bureau of Medicine and Surgery purchase order worth $155 thousand — faces ultimate completion within the next twenty-four months. The Service Contract Inventory dataset shows minimal service-contract activity: $2.6 million in SCI-reportable invoiced revenue across FY2022, 20.4 FTEs in that year, and $0 invoiced in FY2023, with the company appearing in SCI as a named subcontractor on four records in FY2024 and FY2025. SCI-captured prime work carried a median government-paid hourly rate of $60.30 per hour, with zero subcontractor hour engagement on those records. Maxim's federal footprint centers on diagnostic test manufacturing and medical device supply, principally for pandemic-response and defense requirements, without recurring platform-based or vehicle-seated revenue.

Maxim HIV-1 Urine EIA, Cambridge Biotech HIV-1 Serum/Plasma/Urine Western Blot, Oral Fluid HIV EIA/Rapid Test, cGMP Contract Manufacture: BLA/PMA/510(K), Assay Development, Validation, Immunoassay,RIBA, PCR, Multiplex PCR, IHC, Molecular Diagnostic, IVD.